| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Valion Bio, Inc.
$2.91
-0.16 (-5.21%)
Market Cap
12.08 M
EPS
-9.33
P/E Ratio
-
Value Trade
32.50 K
1,867.95 %
Week
871.52 %
1 Month
375.97 %
3 Month
203.96 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
30.78 K
52 Week Range
0.72 - 5.60
% held by Insiders
1.54 %
% held by Institutions
3.69 %
Enterprise Value
10.64 M
Total Shares
4.15 M
Short %
53.23 %
Float Shares
3.09 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ncVNS | — | — | 2025-11-13 | personalizing the stimulation parameters to each user dramatically enhanced autonomic effects Read More | Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) The study demonstrated that personalizing the stimulation parameters to each user dramatically enhance Read More | |
ncVNS | — | — | 2025-11-13 | personalizing the stimulation parameters to each user dramatically enhanced autonomic effects Read More | Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) The study demonstrated that personalizing the stimulation parameters to each user dramatically enhance Read More | |
ncVNS | — | — | 2025-11-13 | personalizing the stimulation parameters to each user dramatically enhanced autonomic effects Read More | Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) The study demonstrated that personalizing the stimulation parameters to each user dramatically enhance Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VBIO▼ -5.2%today
Valion Bio Announces Changes to Management and Board of Directors
Valion Bio has announced significant changes to its management, appointing Lisa Wolf as President and COO while retaining her role as CFO. The company also welcomed new directors Jared Malbin and Thomas Jensen to its Board. These changes aim to enhance operational leadership and capitalize on market opportunities for its lead product candidate, Entolimod.
Read more →VBIO▼ -13%on this news· ran to -31% by day 3
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
Sheba Medical Center has selected Valion Bio's Entolimod for a clinical trial in cancer patients, marking a significant expansion into the neutropenia market. This trial aims to evaluate Entolimod's effectiveness in reducing radiation-induced neutropenia and protecting healthy tissue during radiation therapy. The study is funded by Sheba, allowing Valion to generate data with minimal investment.
Read more →VBIO▼ -7.6%on this news
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
Valion Bio is enhancing its Entolimod platform through strategic initiatives, including government engagement for Acute Radiation Syndrome preparedness and a significant manufacturing scale-up. The company is also expanding into oncology supportive care, demonstrating its evolution into an integrated biotechnology platform. These efforts aim to create multiple avenues for value creation and strengthen its market position.
Read more →VBIO▲ +6.9%on this news
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
Valion Bio, Inc. announced the completion of a protocol design by AFRRI and NIAID to evaluate Entolimod for treating Gastrointestinal Acute Radiation Syndrome (GI-ARS). This development is significant as no FDA-approved treatments currently exist for GI-ARS, representing a critical market opportunity. The protocol aims to generate data necessary for future FDA licensure under the Animal Rule.
Read more →VBIO▼ -24.8%on this news
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Valion Bio confirmed that the U.S. House Armed Services Committee's FY27 NDAA report emphasizes the need for radiation and nuclear countermeasures. The report directs the development of plans for both prophylactic and therapeutic measures. Valion's lead candidate, Entolimod, has shown promise in treating acute radiation syndrome and has received FDA designations. CEO Michael Handley expressed optimism about the prioritization of such countermeasures.
Read more →VBIO▼ -5.6%on this news
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Valion Bio presented its lead candidate, Entolimod, for acute radiation syndrome to senior officials from the U.S. Department of War and BARDA. This engagement reflects growing government interest in Entolimod as a medical countermeasure. The focus on an oral formulation highlights its potential advantages for mass-casualty scenarios. The company aims to advance Entolimod towards a Biologics License Application under the FDA's Animal Rule.
Read more →VBIO▲ +13.6%on this news
Valion Bio Appoints Melinda Lackey as General Counsel Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, MAY 4, 2026 /PRNewswire/ Val
Valion Bio has appointed Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of experience in biopharmaceutical law, particularly in clinical-stage development and intellectual property. This appointment comes as Valion advances its drug candidate, Entolimod, towards FDA regulatory pathways while also expanding its CDMO subsidiary, Velocity Bioworks. Her legal expertise is expected to be pivotal in navigating the company's growth and regulatory challenges ahead.
Read more →VBIOBiotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma
Tivic Health Systems has appointed Michael K. Handley as its new CEO, succeeding Jennifer Ernst. Handley, an experienced leader with a strong background in life sciences, will guide the company as it focuses on late-stage immunotherapies and expands its presence in the biopharma sector. His previous successes in regulatory navigation and product commercialization position him well for this role. Ernst will continue to support Tivic during this transition, underscoring a commitment to ongoing innovation and growth.
Read more →VBIONasdaq: TIVC | www.tivichealth.com ir@tivichealth.com - January 2026 - Jennifer Ernst, CEO, Tivic Health Harnessing the immune system to save lives and improve clinical outcomes Late - stage, highly de - risked assets Co
Tivic Health, led by CEO Jennifer Ernst, is advancing its TLR5 agonist portfolio, particularly the drug Entolimod designed to counteract radiation effects. With a focus on near-term clinical milestones, the company aims to capitalize on high-value opportunities in oncology. The company has already secured significant funding and has an experienced management team in place. The ongoing development and commercialization of its late-stage assets position Tivic as a key player in the market for treating radiation damage and related conditions.
Read more →VBIOTivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package Acquisition creates additional ne
Tivic Health Systems, Inc. has acquired the manufacturing assets of Scorpius Holdings, Inc. to enhance its capacity for producing its lead drug candidate, Entolimod. As part of this move, Tivic is launching Velocity Bioworks, a new subsidiary focused on contract development and manufacturing services. This strategic acquisition, supported by a financing package totaling over $90 million, positions the company to expedite its commercialization efforts and expand development initiatives for various therapeutic applications, particularly in oncology. The transaction aligns with Tivic's mission to lower development costs and reduce lead times typically associated with outsourced manufacturing.
Read more →VBIOTivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) The study demonstrated that personalizing the stimulation parameters to each user dramatically enhance
Tivic Health Systems has reported positive results from its Clinical Optimization Trial on non-invasive cervical vagus nerve stimulation (ncVNS), revealing that personalized stimulation parameters can enhance autonomic effects. The study, conducted in collaboration with The Feinstein Institutes for Medical Research, highlights the importance of various stimulation parameters to achieve consistent outcomes. Despite encouraging findings, the study was conducted with healthy subjects, and further validation in clinical settings is necessary. The company believes these advancements could unlock new opportunities in treating larger patient populations.
Read more →VBIOTivic Receives Two Investigational New Drug Applications for Entolimod for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regu
Tivic Health Systems has received two investigational new drug applications (INDs) for its lead candidate, Entolimod. These INDs are aimed at treating acute radiation syndrome (ARS) and advanced cancers, allowing Tivic to engage the FDA for regulatory clarity and pursue clinical trials for related conditions. Entolimod acts as a TLR5 agonist and has shown promising results in animal models for survival and recovery from radiation effects. The recent developments underscore Tivic's strategic importance in addressing acute medical needs.
Read more →VBIOTivic Reports Second Quarter 2025 Financial Results Company advances its TLR5 agonist program and prepares to report VNS clinical data FREMONT, Calif. –
Tivic Health Systems, Inc. announced its financial results for Q2 2025, showing advancements in its TLR5 agonist program, with plans to exit the ClearUP business. The company has secured financing to support its strategic transformation and is preparing for FDA applications. However, the revenue decreased in comparison to the previous year due to lower consumer health product sales, and the company reported increased operating expenses and net losses. Positive developments include heightened interest in its drug candidate Entolimod for military use and promising data from its bioelectronic device trials.
Read more →VBIOTivic Health Completes Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device Breakthrough Findings to be Reported Later this Year and Applied to Upcoming Phase I Clinical Trial FREMONT, Calif. –
Tivic Health Systems has successfully completed an optimization study for its non-invasive cervical vagus nerve stimulation (ncVNS) device, with results set to be published later this year. The study focused on personalizing device parameters to enhance therapeutic effectiveness, a breakthrough that could pave the way for innovative treatments for various chronic diseases. This advancement aligns with projections indicating substantial growth in the vagus nerve stimulation market, suggesting a promising future for Tivic Health's bioelectronic therapies.
Read more →VBIONasdaq: TIVC A diversified immunotherapeutics company ir@tivichealth.com – May 2025 – Jennifer Ernst, CEO, Tivic Health Safe Harbor This presentation contains forward-looking statements. All statements othe
Tivic Health is advancing its immunotherapeutics portfolio with a newly licensed Phase III program for its TLR5 agonist, Entolimod, which has previously received significant funding. The company has initiated GMP manufacturing to enhance its regulatory application processes and aims to enable sales under emergency use authorizations. With multiple indications in oncology and longevity, Tivic positions itself to tap into a robust immunotherapeutics market over the coming years. Additionally, Entolimod has demonstrated promising survival benefits in preclinical studies for Acute Radiation Syndrome.
Read more →VBIOTivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT FREMONT, Calif. –
Tivic Health Systems, Inc. reported its financial results for the first quarter of 2025, reflecting a strategic shift towards expanding its clinical pipeline in immunotherapy. The company has secured licensing for the Phase III drug Entolimod, with promising applications discussed during briefings at the White House and FDA. Despite a decline in revenue compared to the previous year, Tivic is optimistic about its future, citing new financing agreements and advancements in its non-invasive vagus nerve stimulation program as key developments. The company will hold a conference call to further discuss its results and operational updates.
Read more →VBIOTivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission FREMONT, Calif. –
Tivic Health Systems has announced a GMP manufacturing validation agreement with Scorpius BioManufacturing to prepare for a Biological Licensing Application for its lead candidate, Entolimod, aimed at treating Acute Radiation Syndrome. The $4.1 million program will encompass critical processes necessary for submission to the FDA, including manufacturing scale-up and analytical development. Scorpius will leverage its expertise to ensure a successful filing and plans to utilize its U.S. facility, supporting Tivic's efforts for commercial production following regulatory approval.
Read more →VBIOTivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of its Product Candidates Senior Level Meetings Included Discussion of Tivic's TLR5 and
Tivic Health Systems recently reported positive feedback from briefings held with senior leadership at both the White House and the FDA regarding potential military applications for its product candidates. These discussions included Tivic's TLR5 program and non-invasive cervical vagus nerve stimulation technologies. The meetings indicated a significant interest in advanced treatments for conditions like acute radiation syndrome, potentially benefiting military personnel. Additionally, Tivic is pursuing expedited pathways for FDA approvals for its lead candidate, Entolimod, and other related programs.
Read more →VBIOTivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule FREMONT, Calif. –
Tivic Health Systems, Inc. has announced that it has regained compliance with the Nasdaq minimum bid price listing rule. The company confirmed that its common stock will continue to be traded on the Nasdaq Capital Market under the symbol TIVC. Tivic is developing several therapeutic products, including Entolimod, which is in late-stage studies for treating acute radiation syndrome and has received FDA designations. The company also plans to initiate a phase 2 clinical study for Neutropenia.
Read more →VBIOTivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT FR
Tivic Health Systems, Inc. announced its year-end financial results for 2024, indicating a strategic transformation and growth plan. The company has successfully in-licensed a late-stage biologic, the TLR5 agonist Entolimod, and is advancing its ncVNS devices. While revenues have declined by 33% year-over-year, the company has seen reductions in net loss and plans to enhance its R&D investments. They anticipate upcoming milestones in 2025 related to clinical trials and product advancements, showcasing a focus on innovative therapeutic strategies.
Read more →VBIOTivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System Advances Tivic's Development of Non-Invasive VNS Devices Aimed at Tre
Tivic Health and the Feinstein Institute have presented new findings that suggest a personalized approach to non-invasive vagus nerve stimulation (ncVNS) can effectively optimize the autonomic nervous system's functioning. This method showed promising results, including a significant increase in heart rate variability among participants. The data were showcased at the Sixth Bioelectronic Medicine Summit, emphasizing potential advancements in treating inflammatory, cardiac, and neurological disorders without invasive methods. The collaboration aims to develop scalable bioelectronic therapies with pending patents.
Read more →VBIOTivic Health Systems, Inc. Announces Reverse Stock Split FREMONT, Calif. –
Tivic Health Systems, Inc. has announced a 1-for-17 reverse stock split, effective March 7, 2025, to comply with Nasdaq's minimum bid price requirement. This decision follows stockholder approval at a special meeting on January 31, 2025. The reverse split is part of the company's Compliance Plan, which was presented to Nasdaq in February. Shareholders' ownership interests will remain substantially unchanged, despite adjustments for rounding fractional shares.
Read more →VBIOTIVIC HEALTH NAMES BIOTECH INDUSTRY VETERAN MICHAEL K. HANDLEY TO EXECUTIVE LEADERSHIP TEAM Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following its Licensing of Strategic B
Tivic Health has appointed Michael K. Handley as the President of Tivic Biopharma and Chief Operating Officer of Tivic Health. Handley, an industry veteran, will play a pivotal role in advancing the company's therapeutics pipeline, notably the late-stage product candidate Entolimod. His extensive background includes the successful commercialization of numerous drugs and devices, which Tivic Health aims to leverage for growth. The leadership change coincides with Tivic's strategic licensing deal with Statera Biopharma, aiming to boost its biopharmaceutical capabilities.
Read more →VBIOTivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immu
Tivic Health Systems, Inc. has acquired exclusive worldwide rights to the late-stage TLR5 agonist Entolimod from Statera Biopharma for treating acute radiation syndrome (ARS). This broad licensing agreement positions Tivic as a diversified therapeutics company and allows for future development in additional indications. The agreement includes a potential FDA approval timeline of 24 months and financial terms involving both cash and equity considerations. However, the company faces risks related to regulatory approvals and competition in the market.
Read more →VBIOCEO LETTER TO SHAREHOLDERS ISSUED BY TIVIC HEALTH Provides updates on vagus nerve stimulation (VNS) program and expectations for 2025
Tivic Health Systems published its annual CEO letter, highlighting improvements in its commercial segment and significant developments in its vagus nerve stimulation (VNS) program. The company launched ClearUP 2.0, which improved customer experience and product reviews. VNS is recognized as a growing sector, with projections indicating a market worth $21 billion in the next five years. Tivic's non-invasive VNS technology has shown promising clinical results, and the company plans to advance its clinical trials for 2025, aiming to secure regulatory approvals for new therapies.
Read more →VBIOTivic Reports Third Quarter 2024 Financial Results and Provides Business Update Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT FREMONT, Calif.–
Tivic Health Systems, Inc. announced its third quarter financial results for 2024, highlighting both progress and challenges. The company is focusing on improving the economics of its ClearUP product line and developing a novel non-invasive vagus nerve stimulation system, which has shown promise in Phase 1 trials. However, despite a strategic push for growth, Tivic reported a revenue decrease of 27% and a net loss of $1.4 million in the latest quarter. The overall operational costs have been reduced, and the company is optimistic about its future market potential.
Read more →VBIOTivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment SAN FRANCISCO – (Business Wire) – September XX, 2024 – Tivic Health S
Tivic Health Systems, Inc. has received approval from The Feinstein Institutes' Institutional Review Board to advance its non-invasive cervical vagus nerve stimulation (ncVNS) technology through a new clinical optimization study. This study aims to refine stimulation parameters and enhance the performance of the technology based on physiological measurements. With successful results from a previous Phase 1 study, the current research will support the development of personalized treatment strategies. Additionally, Tivic Health is collaborating with Fletcher Spaght to identify clinical applications that address unmet medical needs.
Read more →VBIOTivic Health Accelerates VNS Commercial Strategy Development Partners with leading growth strategy firm, Fletcher Spaght SAN FRANCISCO – (Business Wire) –
Tivic Health has announced a partnership with Fletcher Spaght to advance its commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS). This collaboration aims to evaluate and prioritize clinical use cases for ncVNS, leveraging insights from clinical outcomes of Tivic's Phase 1 trial. The vagus nerve stimulation market is projected to significantly grow, which could enhance Tivic's market entry opportunities. The company is focused on leveraging this partnership to refine its clinical strategy and product development pipeline for the future.
Read more →VBIOTivic Health Appoints Lisa Wolf as Interim Chief Financial Officer Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor for strategic transactions and special projects SAN FRANCISCO &#x
Tivic Health has appointed Lisa Wolf as its Interim Chief Financial Officer effective October 1, 2024, succeeding Kimberly Bambach. Ms. Bambach will remain with the company in an advisory capacity, focusing on strategic transactions and special projects. Lisa Wolf, who has been part of Tivic's finance team for over two years, brings three decades of financial leadership and a strong understanding of the company’s operations. The transition aims to support Tivic's growth in bioelectronic therapeutics as it advances its product offerings.
Read more →VBIOTivic Reports Second Quarter 2024 Financial Results SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported its second quarter 2024 financial results, highlighting a successful Phase 1 trial for non-invasive vagus nerve stimulation. The company has been focusing on growth strategies, including entering a limited exclusive distribution agreement and launching ClearUP 2.0, which aims to address customer concerns. Despite these advancements, Tivic faced a decrease in revenue and incurred a net loss, though operational efficiencies were noted in the management of expenses. The upcoming earnings call will provide further insights into the company's VNS trial and growth strategies.
Read more →VBIOTivic Health: Christina Valauri Appointed to Board of Directors Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health's Governance Team SAN FRANCISCO
Tivic Health Systems, Inc. has appointed Christina Valauri to its board of directors effective July 1, 2024. Valauri, a seasoned capital markets professional, has been a strategic advisor since April 2023 and has extensive experience in healthcare analysis and management. Her expertise is expected to bolster Tivic Health's governance as the company innovates in bioelectronic medicine. Simultaneously, the company announced the resignation of Karen Drexler from the board, who will continue to support Tivic Health in a strategic advisory role.
Read more →VBIOTivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications SAN FRANCISCO &
Tivic Health has partnered with The Feinstein Institutes to advance its non-invasive cervical vagus nerve stimulation (ncVNS) technology. The initiative will include a 20-person clinical trial aimed at optimizing device specifications based on successful Phase 1 study results, which indicated positive changes in key biomarkers. The company believes this technology could be beneficial for patient populations suffering from conditions such as epilepsy and PTSD. Tivic Health emphasizes its commitment to developing non-invasive solutions that can modulate vagus nerve activity effectively.
Read more →VBIOTivic Reports First Quarter 2024 Financial Results and Subsequent Events SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported its first-quarter financial results for 2024, highlighting a significant reduction in operating loss and an increase in gross profit year-over-year. The company completed enrollment in a clinical study for its non-invasive vagus nerve stimulation technology, indicating progress in its bioelectronic medicine initiatives. Additionally, Tivic announced a successful public offering that raised $4 million, enhancing its financial standing. The ongoing collaboration with Feinstein Institutes further supports the development of innovative treatment solutions in neurology and psychiatry.
Read more →VBIOTivic Health Announces Pricing of $4.0 Million Public Offering
Tivic Health has announced the pricing of a public offering that will raise approximately $4 million through the sale of 4,710,000 shares of common stock and various warrants. The Series A and B warrants will be exercisable immediately at an exercise price of $0.85 per share. The offering, structured by Maxim Group LLC as the placement agent, is expected to close around May 13, 2024, pending customary conditions. This move highlights Tivic Health's ongoing commitment to advancing bioelectronic medicine.
Read more →VBIOTivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems
Tivic Health has announced the successful completion of a clinical trial for its non-invasive cervical vagus nerve stimulation (ncVNS) technology. The study, involving 20 participants, showed significant physiological changes, including a 97% increase in heart rate variability and notable alterations in brain activity. These results suggest that the ncVNS approach may have important clinical applications for conditions such as epilepsy and PTSD. The findings will guide the development of future products in the bioelectronic medicine space.
Read more →VBIOTivic Reports Fiscal Year 2023 Financial Results SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported its financial results for the year ending December 31, 2023, revealing a 36% decrease in revenue to $1.2 million due to lower unit sales of its ClearUP device. Despite challenges, the company successfully streamlined operations and reduced costs, leading to a lower net loss of $8.2 million compared to the previous year. Additionally, Tivic has been recognized for its innovation in bioelectronic medicine, highlighting opportunities for future growth through new clinical programs, including vagus nerve stimulation. A conference call is scheduled to elaborate on the company's performance and strategic direction.
Read more →VBIOTivic Reports Third Quarter 2023 Financial Results 71% Gross Profit Increase; 30% Decrease in Operating Expenses SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported its financial results for the third quarter of 2023, showing a significant 71% increase in gross profit while also reducing operating expenses by 30%. Despite a revenue decline of 40.9% compared to Q3 2022, largely due to a price increase affecting unit sales, the company is optimistic about its future, bolstered by new partnerships and a stronger cash position. The management emphasized improvements made over the last three quarters, highlighting a strategic focus for growth.
Read more →VBIOTivic Health Partners with InStep Health to Access over 2,500 Healthcare Providers and their Patients New Healthcare Provider Program Set to Educate and Drive Patient Awareness of ClearUP
Tivic Health Systems has partnered with InStep Health to promote its bioelectronic device, ClearUP, to over 2,500 healthcare providers and their patients. The initiative, running from November 2023 to February 2024, aims to educate providers and raise awareness among patients, particularly during peak allergy and respiratory infection seasons. ClearUP is designed as a non-invasive treatment option for conditions like allergic rhinitis and sinus infections, highlighting its clinical approval and safety profile. This partnership represents a significant step forward in expanding the medical community's understanding and usage of ClearUP.
Read more →VBIOTivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements
Tivic Health Systems, Inc. has announced that it has regained compliance with the Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This achievement allows Tivic to maintain its presence in the public market under the symbol TIVC. The company specializes in bioelectronic medicine, utilizing patented technology to offer drug-free therapeutic solutions, including its FDA-approved product, ClearUP, designed for treating chronic health conditions.
Read more →VBIOx1f;PRESS RELEASE Tivic Health Systems, Inc. Announces Reverse Stock Split SAN FRANCISCO –
Tivic Health Systems, Inc. has announced a 1-for-100 reverse stock split effective August 23, 2023, in response to Nasdaq's notification of potential delisting due to a low stock price. The reverse split aims to bring the company into compliance with Nasdaq's minimum bid price requirement. Stockholders will receive information regarding their shares post-split with no action required from them. Despite the potential benefits, the company faces uncertainties about the effectiveness of this move in ensuring its continued listing.
Read more →VBIOTivic Reports Second Quarter 2023 Financial Results SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported its financial results for Q2 2023, revealing a gross profit increase to 37.5%, although total revenue fell to $60,000. The company managed a net loss of $2.1 million, an improvement from the previous year. Notable strategic changes included a new distribution agreement with Cardinal Health and a focus on vagus nerve stimulation therapies. A reverse stock split approved by shareholders was also necessary to maintain its Nasdaq listing amid compliance issues.
Read more →VBIOTivic Health Announces Proposed Public Offering of Common Stock SAN FRANCISCO –
Tivic Health Systems, Inc. has announced plans for a proposed public offering of its common stock. The net proceeds from the offering are intended for working capital and general corporate purposes, although completion is subject to market conditions. Maxim Group LLC will serve as the placement agent for this offering. While the company is pursuing growth through this public offering, various risks and uncertainties could affect the final execution and timing of the offering.
Read more →VBIOTivic Health Expands IP Protection with Issuance of Sixth Patent for its Bioelectronic Platform SAN FRANCISCO –
Tivic Health Systems, Inc. has received its sixth patent from the U.S. Patent and Trademark Office for its bioelectronic platform, enhancing its intellectual property portfolio. This patent supports the proprietary technology for delivering bioelectronic treatments, including the recently FDA-approved ClearUP device that treats symptoms of inflammation. Tivic has an additional 17 patents pending, showcasing its commitment to innovation in bioelectronic medicine. The company faces potential risks related to market conditions and operational uncertainties in its future endeavors.
Read more →VBIOLetter from the CEO of Tivic Health, Jennifer Ernst. Tivic Health CEO Provides Additional Information regarding the Company's Current Report on Form 8-K SAN FRANCISCO –
Tivic Health Systems, Inc. announced a letter from CEO Jennifer Ernst addressing the company's delisting notice from Nasdaq due to stock trading below the minimum bid price. The CEO reassures stakeholders that the issue is being actively managed, including appealing the delisting decision and holding a special stockholder meeting to approve a reverse stock split. The company remains focused on compliance with Nasdaq regulations and enhancing shareholder value. Additionally, management has implemented internal restructuring to strengthen the business amidst these challenges.
Read more →VBIOTivic to reconvene Annual Meeting of Stockholders
Tivic Health Systems, Inc. has announced that its Annual Meeting of Stockholders, originally scheduled for June 6, 2023, will reconvene on June 14, 2023. This adjournment is due to the need for additional shareholder votes to approve key proposals. Despite a supportive voting percentage, the company emphasized the importance of further shareholder participation to ensure necessary approvals. Tivic continues to encourage stockholders who have not yet voted to do so before the reconvened meeting date.
Read more →VBIOTivic Reports First Quarter 2023 Financial Results Gross Profit Increase by 61.3%; extends innovation pipeline to include vagus nerve stimulation SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported its first quarter 2023 financial results, highlighting a 61.3% increase in gross profit to $113,000 despite a 12% decline in total revenue to $376,000. The company is broadening its innovation pipeline with the addition of vagus nerve stimulation and has initiated partnerships to support new clinical studies. While the net loss and declining revenues are concerns, the management expressed optimism about turning a corner in profitability and driving growth through expanded product offerings.
Read more →VBIOP R E S S R E L E A S E Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri
Tivic Health Systems, Inc. has announced the appointment of Kimberly Bambach as Interim Chief Financial Officer and Christina Valauri as a strategic advisor to the Board of Directors. Bambach brings over 30 years of financial leadership experience, while Valauri has a robust background in healthcare analytics. These appointments are intended to bolster the company's financial foundation and enhance its strategic growth initiatives. CEO Jennifer Ernst expressed confidence in the immediate positive impact of these new leaders on Tivic's trajectory in the evolving health tech market.
Read more →VBIOTivic, The Feinstein Institutes for Medical Research Announce Pilot Study to Test Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation SAN FRANCISCO , MANHASSET –
Tivic Health Systems, Inc. has announced a pilot clinical study collaboration with The Feinstein Institutes for Medical Research aimed at testing a novel non-invasive bioelectronic device for vagus nerve stimulation. This study seeks to refine stimulation strategies to better target autonomic conditions. Conducted with 20 individuals, it utilizes advanced data analysis from an autonomic nervous system monitoring lab. The partnership highlights the potential for Tivic to broaden its non-invasive treatment offerings in the bioelectronic medicine field.
Read more →VBIOTivic Expands Bioelectronic Portfolio; Files Patent Application for New Approach to Non-Invasive Vagus Nerve Stimulation SAN FRANCISCO –
Tivic Health Systems, Inc. has filed its first patent with the U.S. Patent Office for a new approach to non-invasive Vagus Nerve Stimulation. This patent focuses on a novel circuit design that aims to improve efficacy from existing methods, which could enhance treatments for critical health conditions. Tivic's innovations align with its strategic goal of expanding its bioelectronic medicine portfolio. The company currently holds multiple patents and emphasizes the potential for patient-centric therapies.
Read more →VBIOTivic Health Reports Fiscal Year 2022 Financial Results SAN FRANCISCO – (Business Wire) –
Tivic Health Systems, Inc. reported a strong financial performance for the fiscal year 2022, with a 46% increase in revenue. Direct-to-consumer sales surged by 114%, reflecting a successful strategy to enhance consumer engagement. However, the company faced challenges due to supply chain shortages and market volatility, impacting certain sales channels. Despite these obstacles, the management remains optimistic about future growth prospects as they work to improve product economics.
Read more →VBIOTivic Health Systems, Inc. Announces Pricing of Public Offering SAN FRANCISCO –
Tivic Health Systems, Inc. has priced an underwritten public offering of 20 million shares at $0.25 each, aiming to raise roughly $5 million. Proceeds will help expand sales for its ClearUP product and cover clinical costs for product development. The closing of the offering is anticipated for February 13, 2023, but depends on customary closing conditions. The company has also filed a registration statement with the SEC, outlining the offering details.
Read more →VBIOTivic Health and Reliefband Technologies, LLC Terminate Acquisition Agreement Tivic remains committed to ClearUP growth SAN FRANCISCO –
Tivic Health and Reliefband Technologies, LLC Terminate Acquisition Agreement Tivic remains committed to ClearUP growth SAN FRANCISCO December 9, 2022 Tivic Health Systems, Inc. ( Tivic ) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commerciali
Read more →VBIOTivic Health Signs Agreement with ALOM to Manage Product Supply Chain, Assembly, and Logistics Significant progress made to supply chain to support cost improvements and scaling SAN FRANCISCO –
Tivic Health Signs Agreement with ALOM to Manage Product Supply Chain, Assembly, and Logistics Significant progress made to supply chain to support cost improvements and scaling SAN FRANCISCO December 1, 2022 Tivic Health Systems, Inc. ( Tivic ) (Nasdaq: TIVC), a commercial-pha
Read more →VBIOTivic Health Reports Third Quarter 2022 Financial Results 65% growth in year-to-date revenue 146% increase in unit sales through direct-to-consumer channels for the same period Entered into definitive agree
Tivic Health Reports Third Quarter 2022 Financial Results 65% growth in year-to-date revenue 146% increase in unit sales through direct-to-consumer channels for the same period Entered into definitive agreement to acquire Reliefband SAN FRANCISCO November 14, 2022 Tivic Healt
Read more →VBIOTivic Health to Acquire Assets of Reliefband Company Intends to Dramatically Expand Product Offerings into Bioelectronic Treatment of Nausea CEO to Host Investor Call/Webcast on Wednesday, October 19 th at
Tivic Health to Acquire Assets of Reliefband Company Intends to Dramatically Expand Product Offerings into Bioelectronic Treatment of Nausea CEO to Host Investor Call/Webcast on Wednesday, October 19th at 1:30 PM PT / 4:30 PM SAN FRANCISCO October 17, 2022 Tivic Health Systems
Read more →VBIOMake text into real text. Use vector graphic for logo. 72? Or 150? The future of medicine is electronic. N A S D A Q I N V E S T O R P R E S E N T A T I O N N A S D A Q I N V E S T O R P R E S E N T A T I O N T I V C 2 0
Or 150? The future of medicine is electronic. N A S D A Q I N V E S T O R P R E S E N T A T I O N N A S D A Q I N V E S T O R P R E S E N T A T I O N T I V C 2 0 2 2 S E P T T I V C 2 0 2 2 O C T O B E R F O R W A R D L O O K I N G S T A T E M E N T S This presentationcontains
Read more →VBIOTivic Health Reports Strong Growth in Second Quarter 2022 Financial Results 265% growth in unit sales through direct-to-consumer channels, 97% overall revenue growth vs. Q2 2021 SAN FRANCISCO BAY AREA, CA - (Business Wir
Tivic Health Reports Strong Growth in Second Quarter 2022 Financial Results 265% growth in unit sales through direct-to-consumer channels, 97% overall revenue growth vs. Q2 2021 SAN FRANCISCO BAY AREA, CA - (Business Wire) - August 15, 2022 - Tivic Health Systems, Inc. ("Ti
Read more →VBIOTivic Health Reports First Quarter 2022 Financial Results 77% year-over-year growth in unit sales direct-to-consumer; 219% increase in gross profit.
Tivic Health Reports First Quarter 2022 Financial Results 77% year-over-year growth in unit sales direct-to-consumer; 219% increase in gross profit. SAN FRANCISCO, CA - May 16, 2022 - Tivic Health Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a commercial-phase health techno
Read more →VBIOAPRIL INVESTOR PRESENTATION NASDAQ: TIVC Electrons as Medicine TARGETING INFLAMMATORY RESPONSES WITH BIOELECTRONIC MEDICINE 2 This presentation contains forward - looking statements . All statements other than statements
1 2022 APRIL INVESTOR PRESENTATION NASDAQ: TIVC Electrons as Medicine TARGETING INFLAMMATORY RESPONSES WITH BIOELECTRONIC MEDICINE 2 This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation
Read more →VBIOTivic Health Announces Key Executive Appointments Strengthening Leadership Team Veronica Cai Appointed to Chief Financial Officer; Ryan Sabia Promoted to Chief Operating Officer and Sanjay Ahuja Joined as S
Tivic Health Announces Key Executive Appointments Strengthening Leadership Team Veronica Cai Appointed to Chief Financial Officer; Ryan Sabia Promoted to Chief Operating Officer and Sanjay Ahuja Joined as Senior Vice President, Quality Assurance & Regulatory SAN FRANCISCO, A
Read more →VBIOBioelectronic Medicine NON - INVASIVELY TARGETING IMMUNE SYSTEM RESPONSES 2021 DECEMBER INVESTOR PRESENTATION 2 This presentation contains forward - looking statements . All statements other than statements of historical
1 Bioelectronic Medicine NON - INVASIVELY TARGETING IMMUNE SYSTEM RESPONSES 2021 DECEMBER INVESTOR PRESENTATION 2 This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation may be forward -
Read more →VBIOTivic Health Systems, Inc. Announces Pricing of Initial Public Offering Menlo Park , CA
Tivic Health Systems, Inc. Announces Pricing of Initial Public Offering Park, CA, November 10, 2021 - Tivic Health Systems, Inc. (Nasdaq: TIVC) ("Tivic" or the "Company"), a commercial-phase bioelectronic medicine company, today announced the pricing of its initial public offe
Read more →Competitive Position
How VBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how VBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial